Compare Ginkgo Bioworks Holdings Inc (DNA) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Tenet Healthcare Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M), while Tenet Healthcare Corporation trades at $259.45 (market cap $20.93B). The key difference: Tenet Healthcare Corporation is far larger — about 40.6× Ginkgo Bioworks Holdings Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | THC | |
|---|---|---|
Market Cap | $515.15M | $20.93B |
Sector | Health | Health |
52-Week High | $16.14 | $262.63 |
52-Week Low | $5.48 | $161.37 |
Enterprise Value | $617.10M | $32.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
Tenet Healthcare (THC) trades at $262.13, up 2.14% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $6.12 versus $4.26 expected, while valuation metrics remain attractive with P/E of 10.05 and EV/EBITDA of 5.74. Recent institutional buying and positive earnings revisions support the upward trend.
Outlook remains positive with consensus price target of $281.44 offering 7.4% upside potential. Key risks include healthcare policy headwinds and competitive pressures, but strong ambulatory growth and expense management provide fundamental support. The stock presents a compelling value-growth combination for investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
